Inovio Pharmaceuticals Secures $80.4 Million Judgment in Litigation Against VGXI and GeneOne

Inovio Pharmaceuticals, Inc. has been awarded a judgment of $80.4 million in its litigation against VGXI, Inc. and GeneOne Life Science, which includes $61.8 million in compensatory damages and $18.7 million in legal fees. Despite this legal victory, Inovio expressed concerns that the defendants' financial condition may hinder the collection of the awarded funds. Additionally, the court denied counterclaims from the defendants, resolving certain legal risks for Inovio.